


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
17390 (PC25332A)

In Re Application Of: **John F. Braganza, et al.**



Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/776,953	February 11, 2004	Unassigned	23389	Unassigned	7596

Title: **NOVEL TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
17390 (PC25332A)

In Re Application: **John F. Braganza, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/776,953	February 11, 2004	Unassigned	23389	Unassigned	7596

NOVEL TRIAZOLO-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account **19-1013/SSMP** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on **July 29, 2004** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

Peter I. Bernstein, Esq.

Typed or Printed Name of Person Mailing Certificate


*This certificate may only be used if paying by deposit account.


Signature

Dated: July 29, 2004

Peter I. Bernstein, Esq.
Registration No.: 43,497
Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, NY 11530
PIB/MMR/rjl

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: John F. Braganza, et al. **Examiner:** Unassigned
Serial No.: 10/776,953 **Art Unit:** Unassigned
Filed: February 11, 2004 **Docket:** 17390 (PC25332A)
For: NOVEL TRIAZOLO-PYRIDINES **Dated:** July 29, 2004
AS ANTI-INFLAMMATORY COMPOUNDS

Confirmation No.: 7596

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. U.S. Patent Publication No. 2004/0092547 A1, published May 13, 2004 to Dombroski et al.;
2. U.S. Patent Publication No. 2004/0087615 A1, published May 6, 2004 to Dombroski et al.;
3. U.S. Patent Publication No. 2004/0077682 A1, published April 22, 2004 to Dombroski et al.;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450 on July 29, 2004.

Dated: July 29, 2004


Peter I. Bernstein


4. U.S. Patent Publication No. 2004/0053959 A1, published March 18, 2004 to Buzon, SR. et al.;
5. U.S. Patent Publication No. 2004/0053958 A1, published March 18, 2004 to Dombroski et al.;
6. U.S. Patent No. 6,288,062 B1, issued September 11, 2001 to Adams et al.;
7. U.S. Patent No. 5,716,972, issued February 10, 1998 to Adams et al.;
8. U.S. Patent No. 5,716,955, issued February 10, 1998 to Adams et al.;
9. U.S. Patent No. 4,173,626, issued November 6, 1979 to Dempski et al.;
10. U.S. Patent No. 4,060,598, issued November 29, 1977 to Groppenbacher et al.;
11. U.S. Patent No. 3,538,214, issued November 3, 1970 to Polli et al.;
12. U.S. Patent No. 3,492,397, issued January 27, 1970 to Peters et al.;
13. U.S. Patent No. 3,119,742, issued January 28, 1964 to Heimlich et al.;
14. International Publication No. WO 04/020609 A2, published March 11, 2004;
15. International Publication No. WO 02/072576 A1, published September 19, 2002;
16. International Publication No. WO 02/072579 A1, published September 19, 2002;
17. European Publication No. EP 1 247 810 A1, published October 9, 2002;
18. International Publication No. WO 00/40243, published July 13, 2000;
19. International Publication No. WO 00/63204, published October 26, 2000;
20. International Publication No. WO 00/31065, published June 2, 2000;
21. International Publication No. WO 00/06563, published February 10, 2000;
22. International Publication No. WO 00/41698, published July 20, 2000;
23. Griswold D.E., et al., "Effect of Inhibitors of Eicosanoid Metabolism in Murine Collagen-Induced Arthritis", Arthritis and Rheumatism, 31(11): 1406-1412, (1988);
24. Badger A.M., et al., "Protective Effect of SK&F 86002, a Novel Dual Inhibitor of Arachidonic Acid Metabolism, in Murine Models of Endotoxin

- Shock: Inhibition of Tumor Necrosis Factor as a Possible Mechanism of Action", Circulatory Shock, 27:51-61 (1989);
25. Votta B.J., et al., "Cytokine Suppressive Anti-inflammatory Compounds Inhibit Bone Resorption In Vitro", Bone, 15(5):533-538 (1994);
 26. Lee J.C., et al., "Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors", Annals New York Academy of Sciences, 696:149-170 (1993);
 27. Turner R.B., et al., "Association Between Interleukin-8 Concentration in Nasal Secretions and Severity of Symptoms of Experimental Rhinovirus Colds", Clinical Infectious Diseases, 26:840-846 (1998);
 28. Teran L.M., et al., "Role of Nasal Interleukin-8 in Neutrophil Recruitment and Activation in Children with Virus-Induced Asthma", American Journal of Respiratory and Critical Care Medicine, 155:1362-1366 (1997);
 29. Grünberg K., et al., "Experimental Rhinovirus 16 Infection. Effects on Cell Differentials and Soluble Markers in Sputum in Asthmatic Subjects", American Journal of Respiratory and Critical Care Medicine, 156: 609-616 (1997);
 30. Zhu Z., et al., "Rhinovirus Stimulation of Interleukin-6 In Vivo and In Vitro. Evidence For Nuclear Factor κ B-dependent Transcriptional Activation", The Journal of Clinical Investigation, 97(2):421-430 (1996);
 31. Subauste M.C., et al., "Infection of a Human Respiratory Epithelial Cell Line with Rhinovirus. Induction of Cytokine Release and Modulation of Susceptibility to Infection by Cytokine Exposure", Journal of Clinical Investigation, 96:549-557 (1995); and
 32. Greene, T.W. et al., "The Role of Protective Groups in Organic Synthesis", Protective Groups in Organic Synthesis, 2 Ed.:1-9 (1991).

Applicants are submitting copies of the above-cited references. However, in accordance with the waiver of 37 C.F.R. § 1.98 (a)(2)(i), per 1276 OG 55, Aug. 5, 2003, Applicants are not required to submit a copy of the above-cited U.S. Patent references.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Peter I. Bernstein', written over a horizontal line.

Peter I. Bernstein

Registration No.: 43,497

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343


PIB/MMR/rjl/dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
(REV. 7-80) PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION****Atty. Docket No. (Optional)**

17390 (PC25332A)

Application Number

10/776,953

**Applicant(s)**

John F. Braganza, et al.

Filing Date

February 11, 2004

Group Art Unit

Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	2004/0092547 A1	05/13/04	Dombroski et al.			
	2004/0087615 A1	05/06/04	Dombroski et al.			
	2004/0077682 A1	04/22/04	Dombroski et al.			
	2004/0053959 A1	03/18/04	Buzon, SR. et al.			
	2004/0053958 A1	03/18/04	Dombroski et al.			
	6,288,062 B1	09/11/01	Adams et al.			
	5,716,972	02/10/98	Adams et al.			
	5,716,955	02/10/98	Adams et al.			
	4,173,626	11/06/79	Dempski et al.			

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	WO 04/020609 A2	03/11/04	PCT			YES	NO
	WO 02/072576 A1	09/19/02	PCT				
	WO 02/072579 A1	09/19/02	PCT				
	EP 1 247 810 A1	10/09/02	Europe				
	WO 00/40243	07/13/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Griswold D.E., et al., "Effect of Inhibitors of Eicosanoid Metabolism in Murine Collagen-Induced Arthritis", <u>Arthritis and Rheumatism</u> , 31(11): 1406-1412, (1988)
	Badger A.M., et al., "Protective Effect of SK&F 86002, a Novel Dual Inhibitor of Arachidonic Acid Metabolism, in Murine Models of Endotoxin Shock: Inhibition of Tumor Necrosis Factor as a Possible Mechanism of Action", <u>Circulatory Shock</u> , 27:51-61 (1989)
	Votta B.J., et al., "Cytokine Suppressive Anti-inflammatory Compounds Inhibit Bone Resorption In Vitro", <u>Bone</u> , 15(5):533-538 (1994)
	Lee J.C., et al., "Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors", <u>Annals New York Academy of Sciences</u> , 696:149-170 (1993)

EXAMINER**DATE CONSIDERED**

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (REV. 7-80) PATENT AND TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE	Atty. Docket No. (Optional) 17390 (PC25332A)	Application Number 10/776,953
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Applicant(s) John F. Braganza, et al.	
		Filing Date February 11, 2004	Group Art Unit Unassigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	4,060,598	11/29/77	Groppenbacher et al.			
	3,538,214	11/03/70	Polli et al.			
	3,492,397	01/27/70	Peters et al.			
	3,119,742	01/28/64	Heimlich et al.			

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/63204	10/26/00	PCT				
	WO 00/31065	06/02/00	PCT				
	WO 00/06563	02/10/00	PCT				
	WO 00/41698	07/20/00	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Turner R.B., et al., "Association Between Interleukin-8 Concentration in Nasal Secretions and Severity of Symptoms of Experimental Rhinovirus Colds", <u>Clinical Infectious Diseases</u> , 26:840-846 (1998)
	Teran L.M., et al., "Role of Nasal Interleukin-8 in Neutrophil Recruitment and Activation in Children with Virus-Induced Asthma", <u>American Journal of Respiratory and Critical Care Medicine</u> , 155:1362-1366 (1997)
	Grünberg K., et al., "Experimental Rhinovirus 16 Infection. Effects on Cell Differentials and Soluble Markers in Sputum in Asthmatic Subjects", <u>American Journal of Respiratory and Critical Care Medicine</u> , 156: 609-616 (1997)
	Zhu Z., et al., "Rhinovirus Stimulation of Interleukin-6 In Vivo and In Vitro. Evidence For Nuclear Factor κB-dependent Transcriptional Activation", <u>The Journal of Clinical Investigation</u> , 97(2):421-430 (1996)
EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (REV. 7-80) PATENT AND TRADEMARK OFFICE		U.S. DEPARTMENT OF COMMERCE		Atty. Docket No. (Optional) 17390 (PC25332A)		Application Number 10/776,953		
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant(s) John F. Braganza, et al.				
				Filing Date February 11, 2004		Group Art Unit Unassigned		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)	
FOREIGN PATENT DOCUMENTS								
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
		Subauste M.C., et al., "Infection of a Human Respiratory Epithelial Cell Line with Rhinovirus. Induction of Cytokine Release and Modulation of Susceptibility to Infection by Cytokine Exposure", <u>Journal of Clinical Investigation</u> , 96:549-557 (1995)						
		Greene, T.W. et al., "The Role of Protective Groups in Organic Synthesis", <u>Protective Groups in Organic Synthesis</u> , 2 Ed.:1-9 (1991)						
EXAMINER				DATE CONSIDERED				
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								